These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39119925)

  • 1. Relationship Between Melatonin Receptor Agonists and Parkinson's Disease.
    Noguchi Y; Masuda R; Aizawa H; Yoshimura T
    J Pineal Res; 2024 Aug; 76(5):e13002. PubMed ID: 39119925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.
    Laudon M; Frydman-Marom A
    Int J Mol Sci; 2014 Sep; 15(9):15924-50. PubMed ID: 25207602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders.
    Williams WP; McLin DE; Dressman MA; Neubauer DN
    Pharmacotherapy; 2016 Sep; 36(9):1028-41. PubMed ID: 27500861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in the development of agonists and antagonists for melatonin receptors.
    Zlotos DP
    Curr Med Chem; 2012; 19(21):3532-49. PubMed ID: 22680635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do peripheral melatonin agonists improve bone fracture healing? The effects of agomelatine and ramelteon on experimental bone fracture.
    Köse D; Köse A; Halıcı Z; Gürbüz MA; Aydın A; Ugan RA; Karaman A; Toktay E
    Eur J Pharmacol; 2020 Nov; 887():173577. PubMed ID: 32949602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin agonists and insomnia.
    Ferguson SA; Rajaratnam SM; Dawson D
    Expert Rev Neurother; 2010 Feb; 10(2):305-18. PubMed ID: 20136385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders.
    Geoffroy PA; Etain B; Franchi JA; Bellivier F; Ritter P
    Curr Pharm Des; 2015; 21(23):3352-8. PubMed ID: 26088111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches.
    Hardeland R
    Curr Pharm Des; 2016; 22(8):1086-101. PubMed ID: 25248806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant actions of melatonin and melatonin receptor agonist: Focus on pathophysiology and treatment.
    Wang YQ; Jiang YJ; Zou MS; Liu J; Zhao HQ; Wang YH
    Behav Brain Res; 2022 Feb; 420():113724. PubMed ID: 34929236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics?
    Srinivasan V; Brzezinski A; Pandi-Perumal SR; Spence DW; Cardinali DP; Brown GM
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):913-23. PubMed ID: 21453740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
    Torres R; Kramer WG; Baroldi P
    J Clin Pharmacol; 2015 May; 55(5):525-33. PubMed ID: 25450415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs.
    Srinivasan V; Singh J; Pandi-Perumal SR; Brown GM; Spence DW; Cardinali DP
    Adv Ther; 2010 Nov; 27(11):796-813. PubMed ID: 20827520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
    Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
    Nishimon S; Nishimon M; Nishino S
    Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
    Bonacci JM; Venci JV; Gandhi MA
    J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD; Neville MW
    Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin and its agonists: an update.
    Arendt J; Rajaratnam SM
    Br J Psychiatry; 2008 Oct; 193(4):267-9. PubMed ID: 18827285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ramelteon for the treatment of secondary REM sleep behavior disorder.
    Nomura T; Kawase S; Watanabe Y; Nakashima K
    Intern Med; 2013; 52(18):2123-6. PubMed ID: 24042525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system.
    Hardeland R; Poeggeler B
    Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):189-216. PubMed ID: 22640220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon.
    Pandi-Perumal SR; Srinivasan V; Poeggeler B; Hardeland R; Cardinali DP
    Nat Clin Pract Neurol; 2007 Apr; 3(4):221-8. PubMed ID: 17410109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.